Discontinued
Antibody (Suitable for clinical applications)
Sample Type: FFPE Patient Samples.
Tested Applications: IHC. Approved for In Vitro Diagnostic Procedures on FFPE tissues. For tissue collection recommendations, please see datasheet sent with product.
Application Notes
Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.
| Specification | Recommendation |
|---|---|
| Recommended Dilution (Conc) | 1:50-1:100 |
| Pretreatment | Citrate Buffer pH 6.0 |
| Incubation Parameters | 30 min at Room Temperature |
Clonality: Monoclonal
Anti-CD138 Antibody Clone: EP201
Host and Isotype: Rabbit Rabbit IgG
Recommended Positive Control Sample: Tonsil, Plasmacytoma
Cellular Localization of Antibody EP201 Staining: Membrane
Buffer and Stabilizer: PBS with 1% BSA and 0.05% NaN3
Antibody Concentration: Lot specific. Plese contact tech support for data.
Immunogen: A synthetic peptide corresponding to residues in human CD138 protein
Storage Conditions: This antibody should be stored refrigerated (2-8°C). This product should not be used past the expiration date printed on the vial.
CD138 Information for Pathologists
Summary:
CD138, Aka heparan sulfate proteoglycan, syndecan-1, mediates cell adhesion, and growth factors activity. It is acquired during late stage of B cell differentiation. Loss of CD138 expression is associated with tumor aggressiveness in squamous cell carcinoma (SCC) of head and neck and larynx. CD138 levels also reduced in invasive SCC but not in SCC in situ.Common Uses By Pathologists:
CD138 staining is typically observed in B cell precursors, plasma cells, stratified squamous epithelium, keratoacanthoma, myeloma, plasmablastic lymphoma (strong), primary effusion lymphoma, pyothorax associated lymphoma, and other CD138+ carcinomas. Mature B cells, and other lymphomas (even plasmacytoid lymphomas) are usually negative for CD138. Altered syndecan-1 (CD138) expression has been detected in several different tumor types. Loss of CD138 expression is associated with tumor aggressiveness in squamous cell carcinoma (SCC) of head and neck and larynx; levels also reduced in invasive SCC but not in SCC-in situ.Limitations and Warranty
This antibody is manufactured in accordance with clinical good manufacturing practices in an ISO13485:2016 certified production facility. It is intended for multiple uses including in vitro diagnostic use and research use only applications. Please see vial label for expiration date. We strive to always deliver antibodies with a shelf life of at least two years.
There are no reviews yet.